NASDAQ:CLGN • IL0004960188
The current stock price of CLGN is 0.63 USD. In the past month the price decreased by -59.75%. In the past year, price decreased by -82.25%.
ChartMill assigns a fundamental rating of 3 / 10 to CLGN. While CLGN seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months CLGN reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS increased by 25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -86.31% | ||
| ROE | -130.68% | ||
| Debt/Equity | 0 |
8 analysts have analysed CLGN and the average price target is 11.73 USD. This implies a price increase of 1761.9% is expected in the next year compared to the current price of 0.63.
For the next year, analysts expect an EPS growth of 77.99% and a revenue growth 422.12% for CLGN
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.81 | 397.325B | ||
| AMGN | AMGEN INC | 16.84 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 17.05 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.6 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.98 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.77 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.8 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.02 | 20.385B |
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company. The firm provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
COLLPLANT BIOTECHNOLOGIES LT
4 Oppenheimer Street, P.O. Box 4132
Rehovot 7670104 IL
CEO: Yehiel Tal
Employees: 57
Phone: 972732325600
CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company. The firm provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
The current stock price of CLGN is 0.63 USD. The price increased by 1.61% in the last trading session.
CLGN does not pay a dividend.
CLGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
COLLPLANT BIOTECHNOLOGIES LT (CLGN) currently has 57 employees.
COLLPLANT BIOTECHNOLOGIES LT (CLGN) has a market capitalization of 8.05M USD. This makes CLGN a Nano Cap stock.
The outstanding short interest for COLLPLANT BIOTECHNOLOGIES LT (CLGN) is 1.23% of its float.